Original article by Jared Lynch
The Australian – Page: 15 : 8-Sep-20
Biopharmaceutical giant CSL has secured a $1.7bn deal with the federal government to produce 80 million doses of two coronavirus vaccine candidates. This comprises 30 million doses of the vaccine that is being developed by Oxford University and AstraZeneca, and 50 million doses of the vaccine that CSL is developing with the University of Queensland. Phase three clinical trials have commenced on the Oxford vaccine, while the home-grown vaccine is in phase one trials. The government will contribute $300m to the cost of upgrading CSL’s advanced manufacturing facility in Melbourne to produce the vaccines.
CSL LIMITED – ASX CSL, OXFORD UNIVERSITY, ASTRAZENECA PLC